Open an account

SIGA Technologies

SIGA · NASDAQ

$3.15+$0.01 (+0.32%)TodayMarket closed ·
Prev close $3.14

About SIGA

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The firm is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

Employees
49
Headquarters
New York City, New York
Listed
Sep 9, 1997
Sector
Health Care
Industry
Pharmaceuticals
Website
siga.com

SIGA key statistics

Market cap
225.61M
Price-earnings ratio
0.00
Dividend yield
19.21%
Average volume
617.02K
Volume
263.38K
Open price
$3.15
High today
$3.22
Low today
$3.12
52 Week high
$8.55
52 Week low
$2.83

SIGA Technologies (SIGA) at a glance

As of Oct 20, 2026, SIGA Technologies (SIGA) shares are priced at $3.15, giving the company a market cap of 225.61M, a price-to-earnings ratio of 0.00 and a dividend yield of 19.21%.

Today the stock has traded between $3.12 and $3.22. The current price is 1.0% above the day's low and 2.2% below its high.

Volume so far is 263.38K shares, below the average of 617.02K shares a day.

Over the past year SIGA Technologies has ranged from $2.83 to $8.55, and now sits 6% of the way up that range.

SIGA Technologies met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.17 per share against an estimate of $0.00.

SIGA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 0.0% on average.

  1. Q3 FY24: reported $0.02 per share against an estimate of $0.00
  2. Q4 FY24: reported $0.63 per share against an estimate of $0.00
  3. Q1 FY25: reported -$0.01 per share against an estimate of $0.00
  4. Q2 FY25: reported $0.49 per share against an estimate of $0.00
  5. Q3 FY25: reported -$0.09 per share against an estimate of $0.00
  6. Q4 FY25: reported -$0.08 per share against an estimate of $0.00
  7. Q1 FY26: reported -$0.05 per share against an estimate of $0.00
  8. Q2 FY26: reported $0.17 per share against an estimate of $0.00

SIGA news

  • Earnings Scheduled For November 6, 2025

  • Earnings Scheduled For August 5, 2025

  • Earnings Scheduled For May 8, 2025

  • Watching SIGA Technologies; Shares See Volume To The Upside, Earlier Reports Say NC Department Of Health And Human Services Said Mpox Found In Wastewater In North Carolina From Samples Collected On March 25, March 28 & April 8 From Treatment Plant In Greenville; No Mpox Clade I Cases Have Been Reported To Date

  • Vandana Singh

    NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox

  • 'Tecovirimat Is Safe But Ineffective As Treatment For Clade II Mpox' - NIH

  • Avi Kapoor

    Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

  • 'NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution Or Pain'

Similar companies

Companies in the same industry as SIGA Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.